Recently, the National Cancer Institute released its Annual Report to the Nation on the Status of Cancer. Alarmingly, the report shows that liver cancer-related death rates were highest among people who have had hepatitis B and C.
This is preventable. There has been a vaccine to prevent hepatitis B since 1991, and new drugs for hepatitis C can cure 90% of cases but many people do not know they have it. Hepatitis C can remain silent in a person’s body for decades with symptoms often emerging in late stages of liver disease.
In addition to hepatitis, non-alcoholic fatty liver disease (newly renamed metabolic dysfunction-associated steatotic liver disease or MASLD) increases the risk for liver cancer, and, for those already diagnosed, reduces the chances for survival. Researchers at last year’s International Liver Congress meeting reported that survival is shorter for patients with fatty liver disease (newly renamed to steatotic liver disease) who develop cancer than it is for patients with hepatitis B or hepatitis C who develop liver cancer.
In fact, fatty liver disease is emerging as a major cause of hepatocellular carcinoma in the United States; a recent study found that in a five-year period (2004 to 2009), the annual increase in hepatocellular carcinoma in fatty liver disease patients was approximately 5%.
With as many as 4 million Americans infected with hepatitis C (75% of them do not know they have it), plus the 30% of Americans who have some form of fatty liver disease (this number is poised to reach 50% by 2030), clearly there is cause for concern.
The American Liver Foundation is the country’s only nonprofit organization exclusively dedicated to promoting liver health, as well as education, support and research for the prevention, treatment and cure of liver disease. Learn more about who we are and what we do here.
To read the report, click here.
To learn more about liver cancer, click here.
Last updated on January 17th, 2024 at 03:48 pm